Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - BTIG has lowered its price target on Evolus (NASDAQ:EOLS) to $18.00 from $21.00 while maintaining a Buy rating, following the company’s disappointing second-quarter results. According to InvestingPro data, the stock currently trades at $8.91, significantly below its 52-week high of $17.82. InvestingPro analysis suggests the stock is slightly undervalued at current levels.
Evolus reported Q2 revenue of $69.4 million, up 4% year-over-year but significantly below the consensus estimate of $82.0 million. The company experienced its first-ever decline in Jeuveau sales, which fell approximately 11% year-over-year after customers stopped purchasing vials in the final two weeks of June. Despite recent challenges, InvestingPro data shows the company maintains strong fundamentals with a healthy gross margin of 68.41% and a solid current ratio of 2.34, indicating good short-term liquidity.
In response to continued consumer pressures, Evolus reduced its full-year revenue guidance to $295 million-$305 million, down from its previous forecast of $345 million-$355 million. The company also cut its operating expense guidance to $208 million-$213 million, representing approximately $25 million in cost savings primarily affecting G&A functions.
One bright spot was the strong initial uptake of Evolysse, the company’s injectable HA gels, which contributed $9.7 million in Q2 revenue, significantly exceeding BTIG’s forecast of $3 million. Evolysse is now expected to account for 10-12% of fiscal year 2025 revenue.
Despite the Q2 setback, Evolus maintained its long-range plan of achieving at least $700 million in revenue and a non-GAAP operating margin of at least 20% by 2028, while continuing to expect meaningful profitability in Q4 and annual profitability starting in 2026.
In other recent news, Evolus Inc . reported its financial results for the second quarter of 2025, revealing a wider-than-expected loss. The company posted earnings per share (EPS) of -$0.27, which did not meet analysts’ expectations of -$0.10. Additionally, Evolus generated $69.4 million in revenue, falling short of the projected $82.18 million. These financial figures highlight the challenges Evolus faced during this period. The earnings announcement is a significant development for investors, as it provides insight into the company’s financial health. While the earnings and revenue results were below forecasts, they are critical data points for evaluating the company’s performance. This information is essential for investors considering their positions in Evolus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.